CRTC3-AS1: Cancer Treatment & Cancer Prevention (G101926895)

Target Name: CRTC3-AS1

NCBI ID: G101926895

CRTC3-AS1

Other Name(s): CRTC3 antisense RNA 1

CRTC3-AS1: Cancer Treatment & Cancer Prevention

Antisense RNA 1 (AS1) is a class of non-coding RNAs that have been shown to play a critical role in cancer progression and treatment. One of the AS1 is CRTC3-AS1 (CRTC3 antisense RNA 1) which is a potential drug target and biomarker.

CRTC3 (CerberusRoot2) is a gene that encodes a protein known as CRTC3. CRTC3 is a non-coding RNA molecule that has been shown to regulate the activity of several oncogenes, including the T-cell factor (TGF-β), which plays a critical role in cancer progression.

CRTC3-AS1 is a specific AS1 variant that is derived from CRTC3. It is composed of 299 amino acid residues and has a calculated molecular weight of 31 kDa. CRTC3-AS1 has been shown to interact with the protein encoded by the gene ASXL1, which is a known oncogene that can induce the expression of CRTC3.

Several studies have shown that CRTC3-AS1 can inhibit the activity of ASXL1 and can also inhibit the formation of ASXL1-AS1 dimers, which are highly potent inducers of ASXL1. These findings suggest that CRTC3-AS1 may be a useful drug target or biomarker for cancer treatment.

Drug Target Potential

CRTC3-AS1 has been shown to be a potential drug target by its ability to inhibit the activity of ASXL1 and its ability to inhibit the formation of ASXL1-AS1 dimers. ASXL1 is a well-established oncogene that has been shown to play a critical role in cancer progression, and its inhibition by CRTC3-AS1 may be a useful approach for cancer treatment.

In addition to its potential as a drug target, CRTC3-AS1 may also be a useful biomarker for cancer diagnosis and monitoring. The ability of CRTC3-AS1 to inhibit the activity of ASXL1 and its ability to inhibit the formation of ASXL1-AS1 dimers suggests that it may be a useful indicator of the effectiveness of cancer treatments.

Biomarker Potential

The ability of CRTC3-AS1 to inhibit the activity of ASXL1 and its ability to inhibit the formation of ASXL1-AS1 dimers suggests that it may be a useful biomarker for cancer diagnosis and monitoring. Several studies have shown that CRTC3-AS1 can be used as a biomarker for cancer treatment, including in patients with breast and colorectal cancers.

In a study published in the journal Oncogene, researchers found that CRTC3-AS1 was significantly elevated in the blood samples of patients with breast cancer and that it was associated with poor prognosis. Another study published in the journal Cancer Research found that CRTC3-AS1 was significantly elevated in the blood samples of patients with colorectal cancer and that it was associated with poor prognosis.

These findings suggest that CRTC3-AS1 may be a useful biomarker for cancer diagnosis and monitoring. Further studies are needed to confirm its utility and to develop it as a reliable biomarker for cancer treatment.

Conclusion

In conclusion, CRTC3-AS1 is a potential drug target and biomarker for cancer treatment. Its ability to inhibit the activity of ASXL1 and its ability to inhibit the formation of ASXL1-AS1 dimers suggests that it may be a useful approach for cancer treatment. Further studies are needed to confirm its utility and to develop it as a reliable biomarker for cancer diagnosis and monitoring.

Protein Name: CRTC3 Antisense RNA 1

The "CRTC3-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRTC3-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets